In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries

Autores
Appel, Tobias Manuel; Mojica, Maria Fernanda; De La Cadena, Elsa; Pallares, Cristian; Radice, Marcela Alejandra; Castañeda Méndez, Paulo; Jaime-Villalón, Diego; Gales, Ana; Munita, Jose; Villegas, Maria
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which hasshown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 andOctober 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% ofEnterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America
Fil: Appel, Tobias Manuel. Universidad El Bosque; Colombia
Fil: Mojica, Maria Fernanda. Universidad El Bosque; Colombia
Fil: De La Cadena, Elsa. Universidad El Bosque; Colombia
Fil: Pallares, Cristian. Universidad El Bosque; Colombia
Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Castañeda Méndez, Paulo. Hospital Médica Sur; México
Fil: Jaime-Villalón, Diego. Hospital San Angel; México
Fil: Gales, Ana. Universidade de Sao Paulo; Brasil
Fil: Munita, Jose. No especifíca;
Fil: Villegas, Maria. Universidad El Bosque; Colombia
Materia
Ceftazidime/Avibactam
Enterobacterales
Antibiotic susceptibility
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/109947
Acceder
id CONICETDig_c252f494893952a60d902605ffeb586e
oai_identifier_str oai:ri.conicet.gov.ar:11336/109947
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American CountriesAppel, Tobias ManuelMojica, Maria FernandaDe La Cadena, ElsaPallares, CristianRadice, Marcela AlejandraCastañeda Méndez, PauloJaime-Villalón, DiegoGales, AnaMunita, JoseVillegas, MariaCeftazidime/AvibactamEnterobacteralesAntibiotic susceptibilityhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which hasshown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 andOctober 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% ofEnterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin AmericaFil: Appel, Tobias Manuel. Universidad El Bosque; ColombiaFil: Mojica, Maria Fernanda. Universidad El Bosque; ColombiaFil: De La Cadena, Elsa. Universidad El Bosque; ColombiaFil: Pallares, Cristian. Universidad El Bosque; ColombiaFil: Radice, Marcela Alejandra. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Castañeda Méndez, Paulo. Hospital Médica Sur; MéxicoFil: Jaime-Villalón, Diego. Hospital San Angel; MéxicoFil: Gales, Ana. Universidade de Sao Paulo; BrasilFil: Munita, Jose. No especifíca; Fil: Villegas, Maria. Universidad El Bosque; ColombiaMDPI2020-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/109947Appel, Tobias Manuel; Mojica, Maria Fernanda; De La Cadena, Elsa; Pallares, Cristian; Radice, Marcela Alejandra; et al.; In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries; MDPI; Antibiotics; 9; 2; 2-2020; 1-72079-6382CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3390/antibiotics9020062info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2079-6382/9/2/62info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:56:26Zoai:ri.conicet.gov.ar:11336/109947instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:56:26.292CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
title In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
spellingShingle In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
Appel, Tobias Manuel
Ceftazidime/Avibactam
Enterobacterales
Antibiotic susceptibility
title_short In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
title_full In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
title_fullStr In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
title_full_unstemmed In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
title_sort In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
dc.creator.none.fl_str_mv Appel, Tobias Manuel
Mojica, Maria Fernanda
De La Cadena, Elsa
Pallares, Cristian
Radice, Marcela Alejandra
Castañeda Méndez, Paulo
Jaime-Villalón, Diego
Gales, Ana
Munita, Jose
Villegas, Maria
author Appel, Tobias Manuel
author_facet Appel, Tobias Manuel
Mojica, Maria Fernanda
De La Cadena, Elsa
Pallares, Cristian
Radice, Marcela Alejandra
Castañeda Méndez, Paulo
Jaime-Villalón, Diego
Gales, Ana
Munita, Jose
Villegas, Maria
author_role author
author2 Mojica, Maria Fernanda
De La Cadena, Elsa
Pallares, Cristian
Radice, Marcela Alejandra
Castañeda Méndez, Paulo
Jaime-Villalón, Diego
Gales, Ana
Munita, Jose
Villegas, Maria
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Ceftazidime/Avibactam
Enterobacterales
Antibiotic susceptibility
topic Ceftazidime/Avibactam
Enterobacterales
Antibiotic susceptibility
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which hasshown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 andOctober 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% ofEnterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America
Fil: Appel, Tobias Manuel. Universidad El Bosque; Colombia
Fil: Mojica, Maria Fernanda. Universidad El Bosque; Colombia
Fil: De La Cadena, Elsa. Universidad El Bosque; Colombia
Fil: Pallares, Cristian. Universidad El Bosque; Colombia
Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Castañeda Méndez, Paulo. Hospital Médica Sur; México
Fil: Jaime-Villalón, Diego. Hospital San Angel; México
Fil: Gales, Ana. Universidade de Sao Paulo; Brasil
Fil: Munita, Jose. No especifíca;
Fil: Villegas, Maria. Universidad El Bosque; Colombia
description Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which hasshown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 andOctober 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% ofEnterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America
publishDate 2020
dc.date.none.fl_str_mv 2020-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/109947
Appel, Tobias Manuel; Mojica, Maria Fernanda; De La Cadena, Elsa; Pallares, Cristian; Radice, Marcela Alejandra; et al.; In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries; MDPI; Antibiotics; 9; 2; 2-2020; 1-7
2079-6382
CONICET Digital
CONICET
url http://hdl.handle.net/11336/109947
identifier_str_mv Appel, Tobias Manuel; Mojica, Maria Fernanda; De La Cadena, Elsa; Pallares, Cristian; Radice, Marcela Alejandra; et al.; In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries; MDPI; Antibiotics; 9; 2; 2-2020; 1-7
2079-6382
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3390/antibiotics9020062
info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2079-6382/9/2/62
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782271192825856
score 12.982451

Publicaciones similares